News and Announcements
Analytica (ASX: ALT) Annual Update 2015; Receives 510(k) Clearance with FDA & Raises $2.9m
- Published December 16, 2015 4:05PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
In 2015, Analytica (ASX:ALT) achieved a critical regulatory milestone receiving 510(k) clearance with the US FDA for the PeriCoach, which along with Australian and European approval, allows the company to sell the product globally. Analytica also undertook a rights issue which raised $2.9 million. The company increased its US sales and marketing efforts with a distribution agreement with Currently Technology Inc and a partnership with SalesForce4Hire. Analytica has an exciting year ahead as it drives towards a licensing deal, identifies new market and commercialization opportunities for PeriCoach and accelerates research and development efforts to make further enhancements to the product.
ABOUT ANALYTICA
Analytica Ltd (ASX: ALT) is an Australian medical device manufacturing and commercialisation company. Its lead product, the PeriCoach System, is a novel medical device to treat stress urinary incontinence (SUI) – a condition with significant unmet medical need and huge market potential.
PeriCoach is a medical device that measures the muscles that matter when treating stress urinary incontinence and increases pelvic muscle strength. The device is low-risk with low manufacturing cost and readily scalable production. Analytica already has regulatory approval in US, Europe and Australia with sales underway.